{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Food and Drug Administration approves Orkambi, new cystic fibrosis treatment developed by Vertex Pharmaceuticals; approval is expected to make Vertex consistently profitable for the first time. ", "type_of_material": "News", "word_count": "410", "lead_paragraph": "The drug is the second one brought to market by Vertex and could be effective for more patients than the first drug, Kalydeco.", "pub_date": "2015-07-03T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Orkambi, a New Cystic Fibrosis Drug, Wins F.D.A. Approval", "print_headline": "F.D.A. Approves New Drug for the Treatment of Cystic Fibrosis"}, "snippet": "The drug is the second one brought to market by Vertex and could be effective for more patients than the first drug, Kalydeco.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/07/03/business/orkambi-a-new-cystic-fibrosis-drug-wins-fda-approval.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Vertex Pharmaceuticals Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Cystic Fibrosis", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Biotechnology and Bioengineering", "name": "subject"}], "blog": [], "_id": "55957b6c38f0d82a206e5079", "source": "The New York Times"}